Physician profile
Danish Saeed
NPI 1700927019
$4,827.00
in general payments reported to CMS, 2019-2025
37 companies · $1,695 in 2025
The $1,695 reported for 2025 was more than what 95% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $235 · 2021: $525 · 2022: $320 · 2023: $327 · 2024: $1,484 · 2025: $1,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,506.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $909.43 | 2021-2025 | Airsupra, Breztri, Lokelma |
| Novo Nordisk INC | $543.60 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Radius Health, INC. | $500.44 | 2019-2025 | Tymlos |
| Eisai INC. | $423.43 | 2021-2025 | |
| Lilly USA, LLC | $281.81 | 2020-2025 | Mounjaro, Zepbound |
| Biogen, INC. | $274.63 | 2020-2025 | Leqembi |
| Phathom Pharmaceuticals, INC. | $270.69 | 2024-2025 | Voquezna |
| Braeburn INC. | $230.63 | 2024-2025 | Brixadi |
| Abbvie INC. | $202.61 | 2021-2025 | Qulipta, Vraylar |
| Amgen INC. | $133.37 | 2019-2020 | |
| Exact Sciences Corporation | $115.26 | 2023-2025 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $114.06 | 2019-2021 | |
| Almatica Pharma LLC | $87.69 | 2021-2022 | |
| Philips North America LLC | $62.49 | 2021-2022 | |
| Astellas Pharma US INC | $50.75 | 2024 | Veozah |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $49.63 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $48.92 | 2022 | |
| Indivior INC. | $42.64 | 2024-2025 | Sublocade |
| Dexcom, INC. | $42.32 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $40.32 | 2019-2025 | |
| Gilead Sciences, INC. | $39.62 | 2019-2023 | |
| Lundbeck LLC | $38.89 | 2019-2020 | |
| Eton Pharmaceuticals, INC. | $38.06 | 2021 | |
| Pfizer INC. | $35.61 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $29.25 | 2025 | Opsumit, Uptravi |
| Smith+Nephew, INC. | $25.74 | 2019 | |
| Sun Pharmaceutical Industries INC. | $25.29 | 2021 | |
| Tersera Therapeutics LLC | $23.90 | 2023 | Zoladex |
| Novartis Pharmaceuticals Corporation | $23.34 | 2025 | |
| Alexion Pharmaceuticals, INC. | $20.93 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.37 | 2025 | Caplyta |
| Axonics, INC. | $17.08 | 2021 | |
| Puma Biotechnology, INC. | $16.81 | 2023 | |
| Janssen Pharmaceuticals, INC | $13.37 | 2023 | Xarelto |
| Mylan Specialty L.P. | $11.91 | 2019 | |
| Amarin Pharma, INC. | $11.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danish Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.